Area of research
Internal Medicine · Cardiology and Cardiovascular Medicine
Research interest
Research focused on Rivaroxaban and Venous thromboembolism, with related work in Pulmonary embolism, Thrombosis, Vitamin K antagonist. Notable publications include 'Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism', 'International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer', and 'International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer'.
Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial
Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT)
Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein‐Jr phase 3 dose‐exposure‐response evaluation
Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial
Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies
The diagnostic performance of renal function-adjusted D-dimer testing in individuals suspected of having venous thromboembolism
Risk of recurrent venous thromboembolism according to baseline risk factor profiles
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
Individualised versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome (IDEAL DVT): a multicentre, randomised, single-blind, allocation-concealed, non-inferiority trial
Prevalence of Pulmonary Embolism among Patients Hospitalized for Syncope
Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial of two doses
Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE
Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials
The Impact of Residual Thrombosis on the Long-Term Outcome of Patients with Deep Venous Thrombosis Treated with Conventional Anticoagulation
Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism
Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials
Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment
Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer
Left Bundle-Branch Block Induced by Transcatheter Aortic Valve Implantation Increases Risk of Death